KRT5 and breast carcinoma: Our finding is in agreement with the study by Bhargava et al, 2008 who found that a monoclonal antibody to only K5 (clone XM26) was more sensitive than the K5/6 monoclonal antibodies (clones D5/16B4) in identifying basal-like breast carcinomas and reported a sensitivity of 97% for K5 but only 59% for K5/6 [18].